28700
document
Topical retapamulin ointment ( 1 % , wt/wt ) twice daily for 5 days versus oral cephalexin twice daily for 10 days in the treatment of secondarily infected dermatitis : results of a randomized controlled trial . BACKGROUND New antibacterial agents with activity against pathogenic strains resistant to established antibiotics are needed to treat patients with secondarily infected dermatitis ( SID ) . OBJECTIVE We sought to determine the clinical safety and efficacy of topical retapamulin ointment 1 % versus oral cephalexin for the treatment of SID . METHODS Patients with SID were randomly assigned to retapamulin ointment 1 % ( twice daily [ bid ] ) for 5 days , or oral cephalexin ( 500 mg bid ) for 10 days . The primary efficacy end point was clinical response at follow-up . Secondary outcomes included microbiologic response at follow-up , safety , and compliance . RESULTS Retapamulin was as effective as cephalexin ( clinical success rates at follow-up : 85.9 % and 89.7 % , respectively ) . Microbiologic success rates at follow-up were 87.2 % for retapamulin and 91.8 % for cephalexin . Retapamulin was well tolerated and the topical formulation was preferred over the oral drug . LIMITATIONS An imbalance existed in the number of patients with the clinical outcome " unable to determine " ( 15 retapamulin , 2 cephalexin ) , mainly because of their failure to attend the study visit . If those who failed to attend visits ( who did not withdraw as a result of drug-related events ) are removed from the analysis , the clinical success rates are 89.9 % for retapamulin and 89.7 % for cephalexin . CONCLUSIONS Retapamulin ointment 1 % ( bid ) for 5 days was as effective as oral cephalexin ( bid ) for 10 days in treatment of patients with SID , and was well tolerated .
28701
Intervention_Pharmacological
Topical retapamulin ointment
28702
Intervention_Pharmacological
cephalexin
28703
Intervention_Pharmacological
topical retapamulin ointment
28704
Intervention_Pharmacological
cephalexin
28705
Intervention_Pharmacological
retapamulin ointment
28706
Intervention_Pharmacological
oral cephalexin
28707
Intervention_Pharmacological
Retapamulin
28708
Intervention_Pharmacological
cephalexin
28709
Intervention_Pharmacological
retapamulin
28710
Intervention_Pharmacological
cephalexin
28711
Intervention_Pharmacological
Retapamulin
28712
Intervention_Pharmacological
oral drug
28713
Intervention_Pharmacological
retapamulin
28714
Intervention_Pharmacological
cephalexin
28715
Intervention_Pharmacological
retapamulin
28716
Intervention_Pharmacological
cephalexin
28717
Intervention_Pharmacological
Retapamulin ointment
28718
Intervention_Pharmacological
cephalexin
28719
Outcome_Physical
clinical response
28720
Outcome_Physical
microbiologic response
28721
Outcome_Other
safety
28722
Outcome_Mental
compliance .
28723
Outcome_Physical
Microbiologic success rates
28724
Outcome_Other
tolerated
28725
Participant_Condition
secondarily infected dermatitis :
28726
Participant_Age
patients with secondarily infected dermatitis ( SID ) .
28727
Participant_Condition
Patients with SID
28728
Participant_Condition
patients with SID